NASDAQ:IVA Inventiva (IVA) Stock Price, News & Analysis $3.28 -0.07 (-2.09%) As of 08/1/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Inventiva Stock (NASDAQ:IVA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Inventiva alerts:Sign Up Key Stats Today's Range$3.16▼$3.5850-Day Range$2.98▼$3.6552-Week Range$1.53▼$4.05Volume7,649 shsAverage Volume17,937 shsMarket Capitalization$308.03 millionP/E RatioN/ADividend YieldN/APrice Target$10.40Consensus RatingModerate Buy Company Overview Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France. Read More Inventiva Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreIVA MarketRank™: Inventiva scored higher than 50% of companies evaluated by MarketBeat, and ranked 600th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingInventiva has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageInventiva has received no research coverage in the past 90 days.Read more about Inventiva's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Inventiva are expected to grow in the coming year, from ($2.08) to ($1.85) per share.Read more about Inventiva's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.04% of the outstanding shares of Inventiva have been sold short.Short Interest Ratio / Days to CoverInventiva has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inventiva has recently increased by 392.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInventiva does not currently pay a dividend.Dividend GrowthInventiva does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.04% of the outstanding shares of Inventiva have been sold short.Short Interest Ratio / Days to CoverInventiva has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inventiva has recently increased by 392.00%, indicating that investor sentiment is decreasing significantly. News and Social Media2.1 / 5News Sentiment-0.20 News SentimentInventiva has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Inventiva this week, compared to 2 articles on an average week.Search Interest3 people have searched for IVA on MarketBeat in the last 30 days. MarketBeat Follows6 people have added Inventiva to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inventiva insiders have not sold or bought any company stock.Percentage Held by Insiders32.00% of the stock of Inventiva is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.06% of the stock of Inventiva is held by institutions.Read more about Inventiva's insider trading history. Receive IVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter. Email Address IVA Stock News HeadlinesInventiva Announces Preliminary First-Half 2025 Financial ResultsJuly 31 at 4:25 PM | theglobeandmail.comHalf-Year Review of Inventiva's Liquidity Contract with Kepler CheuvreuxJuly 31 at 4:00 PM | globenewswire.comThis Crypto Is Set to Explode in JanuaryFree summit reveals where Bitcoin goes after $120k Don't miss this rare opportunity to learn directly from the experts who are driving this market…August 2 at 2:00 AM | Crypto 101 Media (Ad)INVENTIVA: Inventiva Reports Preliminary 2025 First-Half Financial InformationJuly 30 at 5:22 AM | finanznachrichten.deInventiva Reports Preliminary 2025 First-Half Financial Information¹July 30 at 5:22 AM | finance.yahoo.comInventiva appoints new R&D president and regulatory affairs executiveJuly 11, 2025 | investing.comInventiva names Jason Campagna as President of R&D and Chief Medical ...July 11, 2025 | finance.yahoo.comInventiva Strengthens Leadership Team Ahead of Key MASH Drug MilestonesJuly 10, 2025 | yahoo.comSee More Headlines IVA Stock Analysis - Frequently Asked Questions How have IVA shares performed this year? Inventiva's stock was trading at $2.14 on January 1st, 2025. Since then, IVA shares have increased by 50.5% and is now trading at $3.22. When did Inventiva IPO? Inventiva (IVA) raised $103 million in an initial public offering on Friday, July 10th 2020. The company issued 7,500,000 shares at a price of $13.68 per share. Jefferies, Stifel and Guggenheim Securities served as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers. Who are Inventiva's major shareholders? Inventiva's top institutional shareholders include Wealth Enhancement Advisory Services LLC (0.02%). How do I buy shares of Inventiva? Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inventiva own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inventiva investors own include Kinross Gold (KGC), Oncobiologics (OTLK), Accuray (ARAY), Carnival (CCL), Alibaba Group (BABA), PayPal (PYPL). Company Calendar Today8/02/2025Next Earnings (Estimated)9/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IVA CIK1756594 Webwww.inventivapharma.com Phone33-3-80-44-75-00FaxN/AEmployees100Year Founded2011Price Target and Rating Average Price Target for Inventiva$10.40 High Price Target$17.00 Low Price Target$3.00 Potential Upside/Downside+223.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.92 Quick Ratio0.92 Sales & Book Value Annual Sales$9.95 million Price / Sales30.96 Cash FlowN/A Price / Cash FlowN/A Book Value($1.21) per share Price / Book-2.66Miscellaneous Outstanding Shares95,660,000Free Float65,050,000Market Cap$308.03 million OptionableNot Optionable Beta0.73 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:IVA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.